Anti-Osteoprotegerin antibody produced in goat

affinity isolated antibody, lyophilized powder

MDL number:

Quality Level

biological source


antibody form

affinity isolated antibody

antibody product type

primary antibodies




lyophilized powder

species reactivity



immunohistochemistry: 5-15 μg/mL
neutralization: suitable
western blot: 0.1-0.2 μg/mL



UniProt accession no.

storage temp.


Gene Information

mouse ... Tnfrsf11b(18383)

General description

Osteoprotegerin (OPG) secreted by osteoblasts and osteogenis stromal stem cells belongs to the TNF receptor superfamily. OPG is expressed in bone marrow, osteoblasts, heart, lung, kidney, thymus, B lymphocytes, chondrocytes and smooth muscle cells. The ratio of OPG and receptor activator of NF-κB Ligand (RANKL) is crucial determining the bone mass. Receptor activator of NF-κB (RANK)/RANKL/OPG axis decides the bone biology. OPG binds RANKL and prevents the activation of osteoclasts, the cells that deplete bone mass. Excess levels of OPG lead to osteopetrosis while deficiency results in osteoporosis. The RANK/RANKL/OPG pathway mediates the activation of multiple pathways such as NF-κB, Akt, JNK, and MAPK
Anti-osteoprotegerin specifically reacts with recombinant mouse OPG. The antibody may cross react with human OPG (25% homology).


The antibody has the ability to neutralize the biological activity of recombinant mouse OPG.


purified recombinant mouse osteoprotegerin expressed in mouse NSO cells.


Anti-osteoprotegerin antibody may be used to neutralize mouse OPG at neutralization dose (ND50) of 0.5-2 μg/ml. The antibody is suitable for immunoblotting at a working concentration of 0.1-0.2 μg/ml.

Physical form

Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline containing carbohydrates.


Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves


NONH for all modes of transport

WGK Germany


Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Brendan F Boyce et al.
Current osteoporosis reports, 5(3), 98-104 (2007-10-11)
Understanding of osteoclast formation and activation has advanced considerably since the discovery of the RANKL/RANK/OPG system in the mid 1990s. Osteoblasts and stromal stem cells express receptor activator of NF-jB ligand (RANKL), which binds to its receptor, RANK, on the...
Anne-Priscille Trouvin et al.
Clinical interventions in aging, 5, 345-354 (2011-01-14)
Bone remodeling requires a precise balance between resorption and formation. It is a complex process that involves numerous factors: hormones, growth factors, vitamins, and cytokines, and notably osteoprotegerin (OPG) and receptor activator for nuclear factor-κB (RANK) ligand. The signaling pathway...
I Silva et al.
Acta reumatologica portuguesa, 36(3), 209-218 (2011-11-25)
The discovery of the receptor activator of nuclear factor-kB (RANK)/RANK Ligand (RANKL)/osteoprotegerin (OPG) pathway contributed to the understanding of how bone formation and resorption were processed and regulated. RANKL and OPG are members of the tumor necrosis factor (TNF) and...
Yang Liu et al.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 45(5), 1759-1771 (2018-03-02)
Bone morphogenetic proteins (BMPs) and BMP receptors widely participate in osteolytic metastasis of breast cancer, while their role in tumor-stromal interaction is largely unknown. In this study, we investigated whether BMP receptor type 1a (BMPR1a) can alter the interaction between...
Joel Jules et al.
Expert opinion on therapeutic targets, 14(9), 923-934 (2010-08-04)
Osteoporosis has become a worldwide health and social issue due to an aging population. Four major antiresorptive drugs (agents capable of inhibiting osteoclast formation and/or function) are currently available on the market: estrogen, selective estrogen receptor modulators (SERMs), bisphosphonates and...




LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon




© 2021年版权归德国达姆施塔特默克集团(Merck KGaA)及/或其附属公司所有。版权所有。